Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,23046292,z-average diameter,"The optimized liquid SMEDDS, composed of Labrafil M 1944 CS/Labrasol/Capryol PGMC (15/75/10%v/v) with 10% w/v fenofibrate gave a z-average diameter of around 240 nm.",Enhancement of oral bioavailability of fenofibrate by solid self-microemulsifying drug delivery systems. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23046292/),,240,736,DB01039,Fenofibrate
,21117499,Cmax,The mean values for the Cmax were 3.08 (+/- 1.69) microg/ml for the test and 3.05 (+/- 1.79) microg/ml for the reference product.,Pharmacokinetics and comparative bioavailability of two fenofibrate capsule formulations in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21117499/),[μg] / [ml],3.08,6207,DB01039,Fenofibrate
,21117499,Cmax,The mean values for the Cmax were 3.08 (+/- 1.69) microg/ml for the test and 3.05 (+/- 1.79) microg/ml for the reference product.,Pharmacokinetics and comparative bioavailability of two fenofibrate capsule formulations in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21117499/),[μg] / [ml],3.05,6208,DB01039,Fenofibrate
,21117499,AUC(0-infinity),"The mean values for the AUC(0-infinity) were 94.5 (+/- 41.5) microg/ml h for the test and 88.2 (+/- 41.4) microg/ml h for thereference, respectively.",Pharmacokinetics and comparative bioavailability of two fenofibrate capsule formulations in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21117499/),[μg] / [h·ml],94.5,6209,DB01039,Fenofibrate
,21117499,AUC(0-infinity),"The mean values for the AUC(0-infinity) were 94.5 (+/- 41.5) microg/ml h for the test and 88.2 (+/- 41.4) microg/ml h for thereference, respectively.",Pharmacokinetics and comparative bioavailability of two fenofibrate capsule formulations in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21117499/),[μg] / [h·ml],88.2,6210,DB01039,Fenofibrate
,23602990,log,"Fenofibrate (FBT) is lipophillic drug used in hypercholesterolemia and hypertriglyceridemia having logP 5.375, low solubility (practically insoluble in water) and low oral bioavailability (36%).",Fabrication of fenofibrate nanocrystals by probe sonication method for enhancement of dissolution rate and oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23602990/),,5.375,12272,DB01039,Fenofibrate
,23602990,oral bioavailability,"Fenofibrate (FBT) is lipophillic drug used in hypercholesterolemia and hypertriglyceridemia having logP 5.375, low solubility (practically insoluble in water) and low oral bioavailability (36%).",Fabrication of fenofibrate nanocrystals by probe sonication method for enhancement of dissolution rate and oral bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23602990/),%,36,12273,DB01039,Fenofibrate
,23602990,saturation solubility,"The saturation solubility of formulation FNS3 in 0.5% and 1% of SLS media found to be 67.51±1.5μg/mL and 107±1.9μg/mL, respectively.",Fabrication of fenofibrate nanocrystals by probe sonication method for enhancement of dissolution rate and oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23602990/),[μg] / [ml],67.51,12274,DB01039,Fenofibrate
,23602990,saturation solubility,"The saturation solubility of formulation FNS3 in 0.5% and 1% of SLS media found to be 67.51±1.5μg/mL and 107±1.9μg/mL, respectively.",Fabrication of fenofibrate nanocrystals by probe sonication method for enhancement of dissolution rate and oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23602990/),[μg] / [ml],107,12275,DB01039,Fenofibrate
,23602990,saturation solubility,"While, the saturation solubility of pure drug in 0.5% and 1% of SLS was found to be 6.02±1.51μg/ml and 23.54±1.54μg/ml, respectively.",Fabrication of fenofibrate nanocrystals by probe sonication method for enhancement of dissolution rate and oral bioavailability. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23602990/),[μg] / [ml],6.02,12276,DB01039,Fenofibrate
,23602990,saturation solubility,"While, the saturation solubility of pure drug in 0.5% and 1% of SLS was found to be 6.02±1.51μg/ml and 23.54±1.54μg/ml, respectively.",Fabrication of fenofibrate nanocrystals by probe sonication method for enhancement of dissolution rate and oral bioavailability. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23602990/),[μg] / [ml],23.54,12277,DB01039,Fenofibrate
up to,21907776,maximum solubility,"The optimal formulation consists of 25% Capryol 90, 27.75% Cremophore EL, 9.25% Transcutol P and 38% water (w/w), with a maximum solubility of fenofibrate up to ∼40.96 mg/mL.",Design of fenofibrate microemulsion for improved bioavailability. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21907776/),[mg] / [ml],∼40.96,18349,DB01039,Fenofibrate
,26834471,solubility,"It demonstrated the highest solubility (32.51±2.41 μg/mL), an excellent dissolution (~85% in 10 minutes), and an oral bioavailability ~2.5-fold better than that of the free drug.",Novel electrosprayed nanospherules for enhanced aqueous solubility and oral bioavailability of poorly water-soluble fenofibrate. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26834471/),[μg] / [ml],32.51,20851,DB01039,Fenofibrate
,26114553,relative bioavailability,The relative bioavailability of OPT was 186.9% in comparison with the commercial reference product.,Development of novel core-shell dual-mesoporous silica nanoparticles for the production of high bioavailable controlled-release fenofibrate tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26114553/),%,186.9,25322,DB01039,Fenofibrate
,29412757,Cmax,"The results indicated that the Cmax (35.34 ± 7.52 vs. 30.43 ± 6.45 μg/mL), t1/2 (6.17 ± 1.15 vs. 4.90 ± 0.82 h) and AUC(0-t) (468.12 ± 35.84 vs. 416.35 ± 32.68 mg h L-1) of fenofibric acid decreased significantly (p < .05).",Effects of triptolide on pharmacokinetics of fenofibrate in rats and its potential mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29412757/),[μg] / [ml],35.34,32767,DB01039,Fenofibrate
,29412757,Cmax,"The results indicated that the Cmax (35.34 ± 7.52 vs. 30.43 ± 6.45 μg/mL), t1/2 (6.17 ± 1.15 vs. 4.90 ± 0.82 h) and AUC(0-t) (468.12 ± 35.84 vs. 416.35 ± 32.68 mg h L-1) of fenofibric acid decreased significantly (p < .05).",Effects of triptolide on pharmacokinetics of fenofibrate in rats and its potential mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29412757/),[μg] / [ml],30.43,32768,DB01039,Fenofibrate
,29412757,t1/2,"The results indicated that the Cmax (35.34 ± 7.52 vs. 30.43 ± 6.45 μg/mL), t1/2 (6.17 ± 1.15 vs. 4.90 ± 0.82 h) and AUC(0-t) (468.12 ± 35.84 vs. 416.35 ± 32.68 mg h L-1) of fenofibric acid decreased significantly (p < .05).",Effects of triptolide on pharmacokinetics of fenofibrate in rats and its potential mechanism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29412757/),h,6.17,32769,DB01039,Fenofibrate
,29412757,t1/2,"The results indicated that the Cmax (35.34 ± 7.52 vs. 30.43 ± 6.45 μg/mL), t1/2 (6.17 ± 1.15 vs. 4.90 ± 0.82 h) and AUC(0-t) (468.12 ± 35.84 vs. 416.35 ± 32.68 mg h L-1) of fenofibric acid decreased significantly (p < .05).",Effects of triptolide on pharmacokinetics of fenofibrate in rats and its potential mechanism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29412757/),h,4.90,32770,DB01039,Fenofibrate
,29412757,AUC(0-t),"The results indicated that the Cmax (35.34 ± 7.52 vs. 30.43 ± 6.45 μg/mL), t1/2 (6.17 ± 1.15 vs. 4.90 ± 0.82 h) and AUC(0-t) (468.12 ± 35.84 vs. 416.35 ± 32.68 mg h L-1) of fenofibric acid decreased significantly (p < .05).",Effects of triptolide on pharmacokinetics of fenofibrate in rats and its potential mechanism. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29412757/),[h·mg] / [l],468.12,32771,DB01039,Fenofibrate
,29412757,AUC(0-t),"The results indicated that the Cmax (35.34 ± 7.52 vs. 30.43 ± 6.45 μg/mL), t1/2 (6.17 ± 1.15 vs. 4.90 ± 0.82 h) and AUC(0-t) (468.12 ± 35.84 vs. 416.35 ± 32.68 mg h L-1) of fenofibric acid decreased significantly (p < .05).",Effects of triptolide on pharmacokinetics of fenofibrate in rats and its potential mechanism. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29412757/),[h·mg] / [l],416.35,32772,DB01039,Fenofibrate
,29412757,Tmax,The Tmax of fenofibric acid increased significantly (p < .05) from 5.12 ± 0.36 to 6.07 ± 0.68 h.,Effects of triptolide on pharmacokinetics of fenofibrate in rats and its potential mechanism. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29412757/),h,5.12,32773,DB01039,Fenofibrate
,29412757,Tmax,The Tmax of fenofibric acid increased significantly (p < .05) from 5.12 ± 0.36 to 6.07 ± 0.68 h.,Effects of triptolide on pharmacokinetics of fenofibrate in rats and its potential mechanism. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29412757/),h,6.07,32774,DB01039,Fenofibrate
,29412757,metabolic stability,"Additionally, the metabolic stability of fenofibrate was prolonged from 35.8 ± 6.2 to 48.6 ± 7.5 min (p < .05) with the pretreatment of triptolide.",Effects of triptolide on pharmacokinetics of fenofibrate in rats and its potential mechanism. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29412757/),min,35.8,32775,DB01039,Fenofibrate
,29412757,metabolic stability,"Additionally, the metabolic stability of fenofibrate was prolonged from 35.8 ± 6.2 to 48.6 ± 7.5 min (p < .05) with the pretreatment of triptolide.",Effects of triptolide on pharmacokinetics of fenofibrate in rats and its potential mechanism. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29412757/),min,48.6,32776,DB01039,Fenofibrate
,32104371,AUCs,"After oral administration, AUCs of the suspension and LCC systems were measured at 131.6853 µg⋅h/ml and 1435.72893 µg⋅h/ml, respectively.",Preparation and pharmacokinetic study of fenofibrate cubic liquid crystalline. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32104371/),[h·μg] / [ml],131.6853,36818,DB01039,Fenofibrate
,32104371,AUCs,"After oral administration, AUCs of the suspension and LCC systems were measured at 131.6853 µg⋅h/ml and 1435.72893 µg⋅h/ml, respectively.",Preparation and pharmacokinetic study of fenofibrate cubic liquid crystalline. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32104371/),[h·μg] / [ml],1435.72893,36819,DB01039,Fenofibrate
,10901144,absolute recovery,"In these conditions, the absolute recovery of fenofibric acid was close to 100% and a linear calibration curve was obtained in the concentration range from 0.25 to 20 microg/ml.",Determination of fenofibric acid in human plasma using automated solid-phase extraction coupled to liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10901144/),%,100,43058,DB01039,Fenofibrate
,26054534,particle size,The mean particle size of SMEDDS formulation after dispersion was about 33.7nm,The in vitro and in vivo evaluation of fenofibrate with a self- microemulsifying formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26054534/),n,33.7,43572,DB01039,Fenofibrate
,26054534,maximum absorption,"Also, the maximum absorption was advanced (2h to 1.25h) with SMEDDS formulation.",The in vitro and in vivo evaluation of fenofibrate with a self- microemulsifying formulation. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26054534/),h,2,43573,DB01039,Fenofibrate
,26054534,maximum absorption,"Also, the maximum absorption was advanced (2h to 1.25h) with SMEDDS formulation.",The in vitro and in vivo evaluation of fenofibrate with a self- microemulsifying formulation. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26054534/),h,1.25,43574,DB01039,Fenofibrate
,20145261,absolute bioavailability,"The absolute bioavailability in the stomach, proximal small bowel, distal small bowel, and colon was approximately 81%, 88%, 84%, and 78%, respectively, for fenofibric acid and 69%, 73%, 66%, and 22%, respectively, for fenofibrate (P < .0001 and P = .033 for fenofibric acid vs fenofibrate in the colon and distal small bowel, respectively).",Comparison of the gastrointestinal absorption and bioavailability of fenofibrate and fenofibric acid in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20145261/),%,81,46263,DB01039,Fenofibrate
,20145261,absolute bioavailability,"The absolute bioavailability in the stomach, proximal small bowel, distal small bowel, and colon was approximately 81%, 88%, 84%, and 78%, respectively, for fenofibric acid and 69%, 73%, 66%, and 22%, respectively, for fenofibrate (P < .0001 and P = .033 for fenofibric acid vs fenofibrate in the colon and distal small bowel, respectively).",Comparison of the gastrointestinal absorption and bioavailability of fenofibrate and fenofibric acid in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20145261/),%,88,46264,DB01039,Fenofibrate
,20145261,absolute bioavailability,"The absolute bioavailability in the stomach, proximal small bowel, distal small bowel, and colon was approximately 81%, 88%, 84%, and 78%, respectively, for fenofibric acid and 69%, 73%, 66%, and 22%, respectively, for fenofibrate (P < .0001 and P = .033 for fenofibric acid vs fenofibrate in the colon and distal small bowel, respectively).",Comparison of the gastrointestinal absorption and bioavailability of fenofibrate and fenofibric acid in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20145261/),%,84,46265,DB01039,Fenofibrate
,20145261,absolute bioavailability,"The absolute bioavailability in the stomach, proximal small bowel, distal small bowel, and colon was approximately 81%, 88%, 84%, and 78%, respectively, for fenofibric acid and 69%, 73%, 66%, and 22%, respectively, for fenofibrate (P < .0001 and P = .033 for fenofibric acid vs fenofibrate in the colon and distal small bowel, respectively).",Comparison of the gastrointestinal absorption and bioavailability of fenofibrate and fenofibric acid in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20145261/),%,78,46266,DB01039,Fenofibrate
,20145261,absolute bioavailability,"The absolute bioavailability in the stomach, proximal small bowel, distal small bowel, and colon was approximately 81%, 88%, 84%, and 78%, respectively, for fenofibric acid and 69%, 73%, 66%, and 22%, respectively, for fenofibrate (P < .0001 and P = .033 for fenofibric acid vs fenofibrate in the colon and distal small bowel, respectively).",Comparison of the gastrointestinal absorption and bioavailability of fenofibrate and fenofibric acid in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20145261/),%,69,46267,DB01039,Fenofibrate
,20145261,absolute bioavailability,"The absolute bioavailability in the stomach, proximal small bowel, distal small bowel, and colon was approximately 81%, 88%, 84%, and 78%, respectively, for fenofibric acid and 69%, 73%, 66%, and 22%, respectively, for fenofibrate (P < .0001 and P = .033 for fenofibric acid vs fenofibrate in the colon and distal small bowel, respectively).",Comparison of the gastrointestinal absorption and bioavailability of fenofibrate and fenofibric acid in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20145261/),%,73,46268,DB01039,Fenofibrate
,20145261,absolute bioavailability,"The absolute bioavailability in the stomach, proximal small bowel, distal small bowel, and colon was approximately 81%, 88%, 84%, and 78%, respectively, for fenofibric acid and 69%, 73%, 66%, and 22%, respectively, for fenofibrate (P < .0001 and P = .033 for fenofibric acid vs fenofibrate in the colon and distal small bowel, respectively).",Comparison of the gastrointestinal absorption and bioavailability of fenofibrate and fenofibric acid in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20145261/),%,66,46269,DB01039,Fenofibrate
,20145261,absolute bioavailability,"The absolute bioavailability in the stomach, proximal small bowel, distal small bowel, and colon was approximately 81%, 88%, 84%, and 78%, respectively, for fenofibric acid and 69%, 73%, 66%, and 22%, respectively, for fenofibrate (P < .0001 and P = .033 for fenofibric acid vs fenofibrate in the colon and distal small bowel, respectively).",Comparison of the gastrointestinal absorption and bioavailability of fenofibrate and fenofibric acid in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20145261/),%,22,46270,DB01039,Fenofibrate
,23500116,so,"While unformulated drug exhibited poor solubility (0.22 μg/mL in FaSSGF and 4.31 μg/mL in FaSSIF-V2(PO4)) and dissolved less than 2% in dissolution tests, the solubility of fenofibrate in the presence of the lipid excipients increased dramatically (e.g., to 65.44 μg/mL in the presence of the Myritol 318/TPGS/Tween 80 SMEDDS) and there was an attendant increase in the dissolution (over 80% from capsules containing the Myritol 318/TPGS/Tween 80 SMEDDS and about 20% from the dispersion of fenofibrate in lipid excipients).",Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23500116/),[μg] / [ml],0.22,71535,DB01039,Fenofibrate
,23500116,so,"While unformulated drug exhibited poor solubility (0.22 μg/mL in FaSSGF and 4.31 μg/mL in FaSSIF-V2(PO4)) and dissolved less than 2% in dissolution tests, the solubility of fenofibrate in the presence of the lipid excipients increased dramatically (e.g., to 65.44 μg/mL in the presence of the Myritol 318/TPGS/Tween 80 SMEDDS) and there was an attendant increase in the dissolution (over 80% from capsules containing the Myritol 318/TPGS/Tween 80 SMEDDS and about 20% from the dispersion of fenofibrate in lipid excipients).",Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23500116/),[μg] / [ml],4.31,71536,DB01039,Fenofibrate
,23500116,solubility,"While unformulated drug exhibited poor solubility (0.22 μg/mL in FaSSGF and 4.31 μg/mL in FaSSIF-V2(PO4)) and dissolved less than 2% in dissolution tests, the solubility of fenofibrate in the presence of the lipid excipients increased dramatically (e.g., to 65.44 μg/mL in the presence of the Myritol 318/TPGS/Tween 80 SMEDDS) and there was an attendant increase in the dissolution (over 80% from capsules containing the Myritol 318/TPGS/Tween 80 SMEDDS and about 20% from the dispersion of fenofibrate in lipid excipients).",Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23500116/),[μg] / [ml],65.44,71537,DB01039,Fenofibrate
,8864797,AUC tau,The following mean values were obtained after administration of the test preparation: AUC tau 184.68 microgramsh/ml; Cmax 13.11 micrograms/ml; PTF: 125.0%.,Comparative steady state study with 2 fenofibrate 250 mg slow release capsules. An example of bioequivalence assessment with a highly variable drug. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864797/),[μgramsh] / [ml],184.68,75872,DB01039,Fenofibrate
,8864797,Cmax,The following mean values were obtained after administration of the test preparation: AUC tau 184.68 microgramsh/ml; Cmax 13.11 micrograms/ml; PTF: 125.0%.,Comparative steady state study with 2 fenofibrate 250 mg slow release capsules. An example of bioequivalence assessment with a highly variable drug. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864797/),[μg] / [ml],13.11,75873,DB01039,Fenofibrate
,8864797,AUC tau,"After administration of the reference formulation the following values were observed: AUC tau 175.91 microgramsh/ml, Cmax 12.27 micrograms/ml, PTF: 120.0%.",Comparative steady state study with 2 fenofibrate 250 mg slow release capsules. An example of bioequivalence assessment with a highly variable drug. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864797/),[μgramsh] / [ml],175.91,75874,DB01039,Fenofibrate
,8864797,Cmax,"After administration of the reference formulation the following values were observed: AUC tau 175.91 microgramsh/ml, Cmax 12.27 micrograms/ml, PTF: 120.0%.",Comparative steady state study with 2 fenofibrate 250 mg slow release capsules. An example of bioequivalence assessment with a highly variable drug. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864797/),[μg] / [ml],12.27,75875,DB01039,Fenofibrate
,31765705,Oral bioavailability,Oral bioavailability of the LbDDS ranged from 27 to 35%.,Using in vitro lipolysis and SPECT/CT in vivo imaging to understand oral absorption of fenofibrate from lipid-based drug delivery systems. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31765705/),%,27 to 35,78666,DB01039,Fenofibrate
>,26577601,recoveries,"The mean recoveries of BBR at three concentrations of 0.2, 20.0, 80.0 ng/mL were >85.6%, and those of FBA at three concentrations of 20.0, 2500.0, 40,000.0 ng/mL were >87.9%.",Development and application of a UPLC-MS/MS method for simultaneous determination of fenofibric acid and berberine in rat plasma: application to the drug-drug pharmacokinetic interaction study of fenofibrate combined with berberine after oral administration in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26577601/),%,85.6,82958,DB01039,Fenofibrate
>,26577601,recoveries,"The mean recoveries of BBR at three concentrations of 0.2, 20.0, 80.0 ng/mL were >85.6%, and those of FBA at three concentrations of 20.0, 2500.0, 40,000.0 ng/mL were >87.9%.",Development and application of a UPLC-MS/MS method for simultaneous determination of fenofibric acid and berberine in rat plasma: application to the drug-drug pharmacokinetic interaction study of fenofibrate combined with berberine after oral administration in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26577601/),%,87.9,82959,DB01039,Fenofibrate
,23754165,droplet size,The mean droplet size of the oil phase in the microemulsion formed by the SMEDDS was 131.1 nm.,In vitro and in vivo evaluation of a self-microemulsifying drug delivery system for the poorly soluble drug fenofibrate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23754165/),,131.1,89670,DB01039,Fenofibrate
,11210669,recovery,The recovery was 84.8% of the total Fa in serum.,Rapid and simple method for detection of fenofibric acid in human serum by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210669/),%,84.8,90466,DB01039,Fenofibrate
,11210669,flow-rate,"The compound was separated isocratically on a reversed phase with acetonitrile and 0.02 M phosphoric acid (55:45, v/v) at a flow-rate of 1.0 ml/min.",Rapid and simple method for detection of fenofibric acid in human serum by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210669/),[ml] / [min],1.0,90467,DB01039,Fenofibrate
,31015003,dissolution rate,"The dissolution rate (%) of fenofibrate at 60 min was significantly improved compared with the solution of raw fenofibrate (19.5% ± 3.7%) by 95.1% ± 2.5% and 93.7% ± 4.1% using the SAS and the CSE process, respectively.",Improvement of the dissolution rate and bioavailability of fenofibrate by the supercritical anti-solvent process. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31015003/),,19,92979,DB01039,Fenofibrate
,15118259,Vmax /Km,"(14)C-Pitavastatin is metabolized with CYP2C9 to 8-hydroxy derivative, but its Vmax /Km was about 2 micro l/min/mg, about 1/8 to 1/100 in comparison to the reported values of other statins, indicating that pitavastatin is hardly metabolized.",[Pharmacological and pharmacokinetic features and clinical effects of pitavastatin (Livalo Tablet)]. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15118259/),[μl] / [mg·min],2,99089,DB01039,Fenofibrate
,21256961,AUC,"However, in vivo bioavailability studies in rats showed the same plasma concentration-time profiles when dosing 10mg/kg halofantrine at two dose levels of F6H8, MCT or F6H8:MCT (1:1) (AUC ranged from 3058 to 3447hng/ml, T(max)∼6.0h, C(max) ranged from 168 to 265mg/ml).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),[hng] / [ml],3058 to 3447,110524,DB01039,Fenofibrate
,21256961,T(max),"However, in vivo bioavailability studies in rats showed the same plasma concentration-time profiles when dosing 10mg/kg halofantrine at two dose levels of F6H8, MCT or F6H8:MCT (1:1) (AUC ranged from 3058 to 3447hng/ml, T(max)∼6.0h, C(max) ranged from 168 to 265mg/ml).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),h,∼6,110525,DB01039,Fenofibrate
,21256961,T(max),"However, in vivo bioavailability studies in rats showed the same plasma concentration-time profiles when dosing 10mg/kg halofantrine at two dose levels of F6H8, MCT or F6H8:MCT (1:1) (AUC ranged from 3058 to 3447hng/ml, T(max)∼6.0h, C(max) ranged from 168 to 265mg/ml).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),h,.0,110526,DB01039,Fenofibrate
,21256961,C(max),"However, in vivo bioavailability studies in rats showed the same plasma concentration-time profiles when dosing 10mg/kg halofantrine at two dose levels of F6H8, MCT or F6H8:MCT (1:1) (AUC ranged from 3058 to 3447hng/ml, T(max)∼6.0h, C(max) ranged from 168 to 265mg/ml).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),[mg] / [ml],168 to 265,110527,DB01039,Fenofibrate
,21256961,T(max),"Generally, the addition of polysorbate 80 shortened the time to reach C(max) (T(max) ranged 1.3-4.5h), but had limited effect on the bioavailability from F6H8 or MCT in combination with polysorbate 80 (4:1) (AUC ranged from 3807 to 4403 (hng/ml)).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),h,1.3-4.5,110528,DB01039,Fenofibrate
,21256961,AUC,"Generally, the addition of polysorbate 80 shortened the time to reach C(max) (T(max) ranged 1.3-4.5h), but had limited effect on the bioavailability from F6H8 or MCT in combination with polysorbate 80 (4:1) (AUC ranged from 3807 to 4403 (hng/ml)).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),[hng] / [ml],3807 to 4403,110529,DB01039,Fenofibrate
,21256961,AUC,"Although a synergistic effect was obtained with halofantrine in F6H8:MCT:polysorbate 80 (2:2:1) (AUC 5574±675hng/ml; mean±SEM), it was not superior to dosing halofantrine in pure polysorbarte 80 (AUC 7370±579hng/ml; mean±SEM).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),[hng] / [ml],5574,110530,DB01039,Fenofibrate
,21256961,AUC,"Although a synergistic effect was obtained with halofantrine in F6H8:MCT:polysorbate 80 (2:2:1) (AUC 5574±675hng/ml; mean±SEM), it was not superior to dosing halofantrine in pure polysorbarte 80 (AUC 7370±579hng/ml; mean±SEM).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),[hng] / [ml],7370,110531,DB01039,Fenofibrate
>,25473287,entrapment efficiency,The obtained FN-PLNs were 186.7 nm in size with an entrapment efficiency of >95%.,Effects of PEGylated lipid nanoparticles on the oral absorption of one BCS II drug: a mechanistic investigation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25473287/),%,95,113726,DB01039,Fenofibrate
,25473287,relative bioavailability,"Further, oral absorption of FN was significantly enhanced using PLNs with relative bioavailability of 123.9% and 157.0% to conventional lipid nanoparticles and a commercial formulation (Lipanthyl(®)), respectively.",Effects of PEGylated lipid nanoparticles on the oral absorption of one BCS II drug: a mechanistic investigation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25473287/),%,123.9,113727,DB01039,Fenofibrate
,25473287,relative bioavailability,"Further, oral absorption of FN was significantly enhanced using PLNs with relative bioavailability of 123.9% and 157.0% to conventional lipid nanoparticles and a commercial formulation (Lipanthyl(®)), respectively.",Effects of PEGylated lipid nanoparticles on the oral absorption of one BCS II drug: a mechanistic investigation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25473287/),%,157.0,113728,DB01039,Fenofibrate
,28631822,bioavailabilities,"In vivo assessment in fasted pigs demonstrated bioavailabilities of 86.69 ± 35.37% with combination of FF-SLC and HPMCAS in capsule form and 75.47 ± 14.58% as a suspension, compared to 19.92 ± 9.89% with the reference formulation.",Mesoporous silica-based dosage forms improve bioavailability of poorly soluble drugs in pigs: case example fenofibrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28631822/),%,86.69,113870,DB01039,Fenofibrate
,28631822,bioavailabilities,"In vivo assessment in fasted pigs demonstrated bioavailabilities of 86.69 ± 35.37% with combination of FF-SLC and HPMCAS in capsule form and 75.47 ± 14.58% as a suspension, compared to 19.92 ± 9.89% with the reference formulation.",Mesoporous silica-based dosage forms improve bioavailability of poorly soluble drugs in pigs: case example fenofibrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28631822/),%,75.47,113871,DB01039,Fenofibrate
,28631822,bioavailabilities,"In vivo assessment in fasted pigs demonstrated bioavailabilities of 86.69 ± 35.37% with combination of FF-SLC and HPMCAS in capsule form and 75.47 ± 14.58% as a suspension, compared to 19.92 ± 9.89% with the reference formulation.",Mesoporous silica-based dosage forms improve bioavailability of poorly soluble drugs in pigs: case example fenofibrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28631822/),%,19.92,113872,DB01039,Fenofibrate
,25679417,bioavailability,"The highest fenofibrate bioavailability was attained from formulations with high Kolliphor ELP/EL levels (25% (w/v)), indicating that these surfactants are the better choice for solubilizing fenofibrate in order to increase the absorption upon oral administration.",Kolliphor surfactants affect solubilization and bioavailability of fenofibrate. Studies of in vitro digestion and absorption in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25679417/),,25,116632,DB01039,Fenofibrate
,27594083,absolute oral bioavailability,The absolute oral bioavailability was 93.4% for choline fenofibrate and 40.0% for fenofibric acid.,Absolute oral bioavailability of fenofibric acid and choline fenofibrate in rats determined by ultra-performance liquid chromatography tandem mass spectrometry. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27594083/),%,93.4,120311,DB01039,Fenofibrate
,27594083,absolute oral bioavailability,The absolute oral bioavailability was 93.4% for choline fenofibrate and 40.0% for fenofibric acid.,Absolute oral bioavailability of fenofibric acid and choline fenofibrate in rats determined by ultra-performance liquid chromatography tandem mass spectrometry. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27594083/),%,40.0,120312,DB01039,Fenofibrate
,16183340,m/,"Ions monitored were m/z 297.0--> 251.0 for CTS, m/z 295.0--> 249.0 for TS II A, and m/z 361.1--> 233.0 for FOFB with argon at a pressure of 0.2 Pa and collision energy of 25 eV for collision-induced dissociation (CID).",Determination of cryptotanshinone and its metabolite in rat plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16183340/),,297.0,136873,DB01039,Fenofibrate
,16183340,m/z,"Ions monitored were m/z 297.0--> 251.0 for CTS, m/z 295.0--> 249.0 for TS II A, and m/z 361.1--> 233.0 for FOFB with argon at a pressure of 0.2 Pa and collision energy of 25 eV for collision-induced dissociation (CID).",Determination of cryptotanshinone and its metabolite in rat plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16183340/),,295.0,136874,DB01039,Fenofibrate
,16183340,m/z,"Ions monitored were m/z 297.0--> 251.0 for CTS, m/z 295.0--> 249.0 for TS II A, and m/z 361.1--> 233.0 for FOFB with argon at a pressure of 0.2 Pa and collision energy of 25 eV for collision-induced dissociation (CID).",Determination of cryptotanshinone and its metabolite in rat plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16183340/),,249.0,136875,DB01039,Fenofibrate
,16183340,m/z,"Ions monitored were m/z 297.0--> 251.0 for CTS, m/z 295.0--> 249.0 for TS II A, and m/z 361.1--> 233.0 for FOFB with argon at a pressure of 0.2 Pa and collision energy of 25 eV for collision-induced dissociation (CID).",Determination of cryptotanshinone and its metabolite in rat plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16183340/),,361.1,136876,DB01039,Fenofibrate
,16183340,m/z,"Ions monitored were m/z 297.0--> 251.0 for CTS, m/z 295.0--> 249.0 for TS II A, and m/z 361.1--> 233.0 for FOFB with argon at a pressure of 0.2 Pa and collision energy of 25 eV for collision-induced dissociation (CID).",Determination of cryptotanshinone and its metabolite in rat plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16183340/),,233.0,136877,DB01039,Fenofibrate
,16183340,recoveries,"The average recoveries of CTS and TS II A from rat plasma were 93.7 and 94.7%, respectively.",Determination of cryptotanshinone and its metabolite in rat plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16183340/),%,93.7,136878,DB01039,Fenofibrate
,16183340,recoveries,"The average recoveries of CTS and TS II A from rat plasma were 93.7 and 94.7%, respectively.",Determination of cryptotanshinone and its metabolite in rat plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16183340/),%,94.7,136879,DB01039,Fenofibrate
greater,26024820,Plasma concentrations,"Plasma concentrations greater than 1,000 ng/ml were maintained from 30 min to 8h, suggesting a sustained release pattern.",Novel fenofibric acid-loaded controlled release pellet bioequivalent to choline fenofibrate-loaded commercial product in beagle dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26024820/),[ng] / [ml],"1,000",141110,DB01039,Fenofibrate
,28561239,flow rate,"The mobile phase, 0.02 M ammonium acetate buffer:acetonitrile (35:65, v/v), was run at a flow rate of 1.0 mL/min, and the column eluent was monitored using an ultraviolet detector at 280 nm at room temperature.",Determination of Fenofibric Acid in Rat Plasma and its Application to a Comparative Pharmacokinetic Study of JW322 and Fenofibrate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28561239/),[ml] / [min],1.0,141985,DB01039,Fenofibrate
,28561239,retention times,"The retention times of sildenafil (an internal standard), and fenofibric acid were approximately 5.9 and 7.7 min, respectively.",Determination of Fenofibric Acid in Rat Plasma and its Application to a Comparative Pharmacokinetic Study of JW322 and Fenofibrate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28561239/),min,5.9,141986,DB01039,Fenofibrate
,28561239,retention times,"The retention times of sildenafil (an internal standard), and fenofibric acid were approximately 5.9 and 7.7 min, respectively.",Determination of Fenofibric Acid in Rat Plasma and its Application to a Comparative Pharmacokinetic Study of JW322 and Fenofibrate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28561239/),min,7.7,141987,DB01039,Fenofibrate
,28561239,relative bioavailability,"After oral administration (20 mg/kg) of JW322, relative bioavailability was approximately 272.8% compared to fenofibrate.",Determination of Fenofibric Acid in Rat Plasma and its Application to a Comparative Pharmacokinetic Study of JW322 and Fenofibrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28561239/),%,272.8,141988,DB01039,Fenofibrate
,15907580,oral bioavailability,The oral bioavailability of FNB from these self-assemblies revealed 156% and 15% increases vs.,Enhancement of oral bioavailability of poorly water-soluble drugs by poly(ethylene glycol)-block-poly(alkyl acrylate-co-methacrylic acid) self-assemblies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907580/),%,156,152632,DB01039,Fenofibrate
,15907580,oral bioavailability,The oral bioavailability of FNB from these self-assemblies revealed 156% and 15% increases vs.,Enhancement of oral bioavailability of poorly water-soluble drugs by poly(ethylene glycol)-block-poly(alkyl acrylate-co-methacrylic acid) self-assemblies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907580/),%,15,152633,DB01039,Fenofibrate
,1425874,Cy trough levels,"Fenofibrate 200 mg once daily significantly reduced blood lipids (cholesterol 6.5 vs 7.7 mmol/l; apoprotein B 1.2 vs 1.6 g/l) but did not modify mean whole blood Cy trough levels (113 before fenofibrate vs 103 ng.ml-1), Cmax (812 ng.","Pharmacokinetics of cyclosporine in hyperlipidaemic long-term survivors of heart transplantation. Lack of interaction with the lipid-lowering agent, fenofibrate. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425874/),[ng] / [ml],113,156044,DB01039,Fenofibrate
,1425874,Cy trough levels,"Fenofibrate 200 mg once daily significantly reduced blood lipids (cholesterol 6.5 vs 7.7 mmol/l; apoprotein B 1.2 vs 1.6 g/l) but did not modify mean whole blood Cy trough levels (113 before fenofibrate vs 103 ng.ml-1), Cmax (812 ng.","Pharmacokinetics of cyclosporine in hyperlipidaemic long-term survivors of heart transplantation. Lack of interaction with the lipid-lowering agent, fenofibrate. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425874/),[ng] / [ml],103,156045,DB01039,Fenofibrate
,1425874,Cmax,"Fenofibrate 200 mg once daily significantly reduced blood lipids (cholesterol 6.5 vs 7.7 mmol/l; apoprotein B 1.2 vs 1.6 g/l) but did not modify mean whole blood Cy trough levels (113 before fenofibrate vs 103 ng.ml-1), Cmax (812 ng.","Pharmacokinetics of cyclosporine in hyperlipidaemic long-term survivors of heart transplantation. Lack of interaction with the lipid-lowering agent, fenofibrate. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425874/),ng,812,156046,DB01039,Fenofibrate
,1425874,tmax,"ml-1 by HPLC before fenofibrate versus 865 and 741 respectively, during fenofibrate); tmax (1.6 and 1.7 h before fenofibrate versus 1.4 and 1.4 h respectively), and t1/2 (13.9 and 11.1 h versus 9.5 and 10.7 h).","Pharmacokinetics of cyclosporine in hyperlipidaemic long-term survivors of heart transplantation. Lack of interaction with the lipid-lowering agent, fenofibrate. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425874/),h,1.6,156047,DB01039,Fenofibrate
,1425874,tmax,"ml-1 by HPLC before fenofibrate versus 865 and 741 respectively, during fenofibrate); tmax (1.6 and 1.7 h before fenofibrate versus 1.4 and 1.4 h respectively), and t1/2 (13.9 and 11.1 h versus 9.5 and 10.7 h).","Pharmacokinetics of cyclosporine in hyperlipidaemic long-term survivors of heart transplantation. Lack of interaction with the lipid-lowering agent, fenofibrate. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425874/),h,1.7,156048,DB01039,Fenofibrate
,1425874,tmax,"ml-1 by HPLC before fenofibrate versus 865 and 741 respectively, during fenofibrate); tmax (1.6 and 1.7 h before fenofibrate versus 1.4 and 1.4 h respectively), and t1/2 (13.9 and 11.1 h versus 9.5 and 10.7 h).","Pharmacokinetics of cyclosporine in hyperlipidaemic long-term survivors of heart transplantation. Lack of interaction with the lipid-lowering agent, fenofibrate. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425874/),h,1.4,156049,DB01039,Fenofibrate
,1425874,t1/2,"ml-1 by HPLC before fenofibrate versus 865 and 741 respectively, during fenofibrate); tmax (1.6 and 1.7 h before fenofibrate versus 1.4 and 1.4 h respectively), and t1/2 (13.9 and 11.1 h versus 9.5 and 10.7 h).","Pharmacokinetics of cyclosporine in hyperlipidaemic long-term survivors of heart transplantation. Lack of interaction with the lipid-lowering agent, fenofibrate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425874/),h,13.9,156050,DB01039,Fenofibrate
,1425874,t1/2,"ml-1 by HPLC before fenofibrate versus 865 and 741 respectively, during fenofibrate); tmax (1.6 and 1.7 h before fenofibrate versus 1.4 and 1.4 h respectively), and t1/2 (13.9 and 11.1 h versus 9.5 and 10.7 h).","Pharmacokinetics of cyclosporine in hyperlipidaemic long-term survivors of heart transplantation. Lack of interaction with the lipid-lowering agent, fenofibrate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425874/),h,11.1,156051,DB01039,Fenofibrate
,1425874,t1/2,"ml-1 by HPLC before fenofibrate versus 865 and 741 respectively, during fenofibrate); tmax (1.6 and 1.7 h before fenofibrate versus 1.4 and 1.4 h respectively), and t1/2 (13.9 and 11.1 h versus 9.5 and 10.7 h).","Pharmacokinetics of cyclosporine in hyperlipidaemic long-term survivors of heart transplantation. Lack of interaction with the lipid-lowering agent, fenofibrate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425874/),h,9.5,156052,DB01039,Fenofibrate
,1425874,t1/2,"ml-1 by HPLC before fenofibrate versus 865 and 741 respectively, during fenofibrate); tmax (1.6 and 1.7 h before fenofibrate versus 1.4 and 1.4 h respectively), and t1/2 (13.9 and 11.1 h versus 9.5 and 10.7 h).","Pharmacokinetics of cyclosporine in hyperlipidaemic long-term survivors of heart transplantation. Lack of interaction with the lipid-lowering agent, fenofibrate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425874/),h,10.7,156053,DB01039,Fenofibrate
,15373931,half-life,The mean half-life of repaglinide was 1.3 h in all phases.,Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15373931/),h,1.3,158397,DB01039,Fenofibrate
,25344439,drug release,"At the end of a 5-h in vitro dissolution study, a SLN formulation released 92-93% of drug, whereas drug release was approximately 65 and 45% for the marketed micronized formulation and crude drug, respectively.",Continuous production of fenofibrate solid lipid nanoparticles by hot-melt extrusion technology: a systematic study based on a quality by design approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25344439/),%,65,172198,DB01039,Fenofibrate
,25344439,drug release,"At the end of a 5-h in vitro dissolution study, a SLN formulation released 92-93% of drug, whereas drug release was approximately 65 and 45% for the marketed micronized formulation and crude drug, respectively.",Continuous production of fenofibrate solid lipid nanoparticles by hot-melt extrusion technology: a systematic study based on a quality by design approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25344439/),%,45,172199,DB01039,Fenofibrate
,15871634,terminal half-life,The estimated terminal half-life of ezetimibe and ezetimibe-glucuronide is approximately 22 hours.,"Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871634/),h,22,188555,DB01039,Fenofibrate
below,32906001,polydispersity index,All NLC formulations demonstrated a particle size of approximately 200 nm and a polydispersity index below 0.3.,Chitosan-coated nanostructured lipid carriers of fenofibrate with enhanced oral bioavailability and efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32906001/),,0.3,202500,DB01039,Fenofibrate
above,32906001,encapsulation efficiencies,The encapsulation efficiencies of the NLC formulations were above 85%.,Chitosan-coated nanostructured lipid carriers of fenofibrate with enhanced oral bioavailability and efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32906001/),%,85,202501,DB01039,Fenofibrate
,16502765,tmax,"A slightly prolonged tmax was observed following HFF conditions (4.3 +/- 1.9 hours, versus 3.6 +/- 1.2 hours and 2.3 +/- 0.7 hours under LFF and fasting conditions, respectively), without any effect on mean Cmax.",Absence of a food effect with a 145 mg nanoparticle fenofibrate tablet formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16502765/),h,4.3,204475,DB01039,Fenofibrate
,16502765,tmax,"A slightly prolonged tmax was observed following HFF conditions (4.3 +/- 1.9 hours, versus 3.6 +/- 1.2 hours and 2.3 +/- 0.7 hours under LFF and fasting conditions, respectively), without any effect on mean Cmax.",Absence of a food effect with a 145 mg nanoparticle fenofibrate tablet formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16502765/),h,3.6,204476,DB01039,Fenofibrate
,16502765,tmax,"A slightly prolonged tmax was observed following HFF conditions (4.3 +/- 1.9 hours, versus 3.6 +/- 1.2 hours and 2.3 +/- 0.7 hours under LFF and fasting conditions, respectively), without any effect on mean Cmax.",Absence of a food effect with a 145 mg nanoparticle fenofibrate tablet formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16502765/),h,2.3,204477,DB01039,Fenofibrate
,3318449,plasma half-life,"In normal persons, at steady state with usual doses of 100 mg three times daily, the plasma half-life approximates 30 hours.",Pharmacology of fenofibrate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3318449/),h,30,209208,DB01039,Fenofibrate
,28223873,isocratic flow,The isocratic flow was 0.3 ml/min with rapid run time of 2.5 min and UV detection was at 284 nm.,Development and validation of bioanalytical UHPLC-UV method for simultaneous analysis of unchanged fenofibrate and its metabolite fenofibric acid in rat plasma: Application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28223873/),[ml] / [min],0.3,211633,DB01039,Fenofibrate
,28223873,rapid run time,The isocratic flow was 0.3 ml/min with rapid run time of 2.5 min and UV detection was at 284 nm.,Development and validation of bioanalytical UHPLC-UV method for simultaneous analysis of unchanged fenofibrate and its metabolite fenofibric acid in rat plasma: Application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28223873/),min,2.5,211634,DB01039,Fenofibrate
,30613135,relative bioavailabilities,"The relative bioavailabilities of R1 and R2 were 100.4% and 201.1%, respectively, which were higher than that of Lipilfen® (67.2%).",Fenofibrate modified-release pellets with lag phase and high oral bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30613135/),%,100.4,216435,DB01039,Fenofibrate
,30613135,relative bioavailabilities,"The relative bioavailabilities of R1 and R2 were 100.4% and 201.1%, respectively, which were higher than that of Lipilfen® (67.2%).",Fenofibrate modified-release pellets with lag phase and high oral bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30613135/),%,201.1,216436,DB01039,Fenofibrate
,30613135,relative bioavailabilities,"The relative bioavailabilities of R1 and R2 were 100.4% and 201.1%, respectively, which were higher than that of Lipilfen® (67.2%).",Fenofibrate modified-release pellets with lag phase and high oral bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30613135/),%,67.2,216437,DB01039,Fenofibrate
,26296710,molar extinction coefficient,"FF and FA exhibited intensive UV absorption, with molar extinction coefficient values of 17,000 (290 nm) and 14,000 M(-1)cm(-1) (295 nm), respectively.",New Photosafety Assessment Strategy Based on the Photochemical and Pharmacokinetic Properties of Both Parent Chemicals and Metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26296710/),1/[M],"17,000",225242,DB01039,Fenofibrate
,26296710,molar extinction coefficient,"FF and FA exhibited intensive UV absorption, with molar extinction coefficient values of 17,000 (290 nm) and 14,000 M(-1)cm(-1) (295 nm), respectively.",New Photosafety Assessment Strategy Based on the Photochemical and Pharmacokinetic Properties of Both Parent Chemicals and Metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26296710/),1/[M],"14,000",225243,DB01039,Fenofibrate
up to,28287050,proth,"Anticoagulant activity significantly increased, with prothrombin time (PT) up to 199 ± 33 s in coadministered group (approximately ten-fold compared with rats received warfarin alone).",The effect of fenofibric acid on the pharmacokinetics and pharmacodynamics of warfarin in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28287050/),s,199,231253,DB01039,Fenofibrate
,28287050,IC50,"Incubation experiments illustrated FA inhibited CYP2C6 and CYP3A1/2 with the IC50 values of 6.98 and 16.14 μM, and inhibited the metabolism of warfarin (Ki value of 2.21 μM).",The effect of fenofibric acid on the pharmacokinetics and pharmacodynamics of warfarin in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28287050/),μM,6.98,231254,DB01039,Fenofibrate
,28287050,IC50,"Incubation experiments illustrated FA inhibited CYP2C6 and CYP3A1/2 with the IC50 values of 6.98 and 16.14 μM, and inhibited the metabolism of warfarin (Ki value of 2.21 μM).",The effect of fenofibric acid on the pharmacokinetics and pharmacodynamics of warfarin in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28287050/),μM,16.14,231255,DB01039,Fenofibrate
,28287050,Ki,"Incubation experiments illustrated FA inhibited CYP2C6 and CYP3A1/2 with the IC50 values of 6.98 and 16.14 μM, and inhibited the metabolism of warfarin (Ki value of 2.21 μM).",The effect of fenofibric acid on the pharmacokinetics and pharmacodynamics of warfarin in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28287050/),μM,2.21,231256,DB01039,Fenofibrate
,19353730,flow-rate,"The method involves simple, one-step liquid-liquid extraction procedure coupled with an Acquity UPLC(TM) BEH C(18) column (50 x 2.1 mm, i.d., 1.7 microm) with isocratic elution at a flow-rate of 0.2 mL/min and mefenamic acid was used as the internal standard.",Determination of fenofibric acid in human plasma by ultra performance liquid chromatography-electrospray ionization mass spectrometry: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19353730/),[ml] / [min],0.2,233667,DB01039,Fenofibrate
,19353730,recovery,"The recovery was 66.7% and 52.6% for fenofibric acid, and mefenamic acid, respectively.",Determination of fenofibric acid in human plasma by ultra performance liquid chromatography-electrospray ionization mass spectrometry: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19353730/),%,66.7,233668,DB01039,Fenofibrate
,19353730,recovery,"The recovery was 66.7% and 52.6% for fenofibric acid, and mefenamic acid, respectively.",Determination of fenofibric acid in human plasma by ultra performance liquid chromatography-electrospray ionization mass spectrometry: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19353730/),%,52.6,233669,DB01039,Fenofibrate
,19353730,Total run time,"Total run time was 1.8 min only for each sample, which makes it possible to analyze more than 350 samples per day.",Determination of fenofibric acid in human plasma by ultra performance liquid chromatography-electrospray ionization mass spectrometry: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19353730/),min,1.8,233670,DB01039,Fenofibrate
,20818965,area under the plasma concentration-time curve (AUC((0-t)),"The results suggested that both the area under the plasma concentration-time curve (AUC((0-t)) = 46.83 +/- 11.09 microg/mL h) and the mean peak concentration of the test (C(max) = 4.63 +/- 1.71 microg/mL) were higher than the reference (AUC((0-t)) = 35.12 +/- 10.97 microg/mL h, C(max) = 2.11 +/- 0.08 microg/mL).",Preparation of fenofibrate immediate-release tablets involving wet grinding for improved bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20818965/),[μg] / [h·ml],46.83,234437,DB01039,Fenofibrate
,20818965,peak concentration,"The results suggested that both the area under the plasma concentration-time curve (AUC((0-t)) = 46.83 +/- 11.09 microg/mL h) and the mean peak concentration of the test (C(max) = 4.63 +/- 1.71 microg/mL) were higher than the reference (AUC((0-t)) = 35.12 +/- 10.97 microg/mL h, C(max) = 2.11 +/- 0.08 microg/mL).",Preparation of fenofibrate immediate-release tablets involving wet grinding for improved bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20818965/),[μg] / [ml],4.63,234438,DB01039,Fenofibrate
,20818965,AUC((0-t)),"The results suggested that both the area under the plasma concentration-time curve (AUC((0-t)) = 46.83 +/- 11.09 microg/mL h) and the mean peak concentration of the test (C(max) = 4.63 +/- 1.71 microg/mL) were higher than the reference (AUC((0-t)) = 35.12 +/- 10.97 microg/mL h, C(max) = 2.11 +/- 0.08 microg/mL).",Preparation of fenofibrate immediate-release tablets involving wet grinding for improved bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20818965/),[μg] / [h·ml],35.12,234439,DB01039,Fenofibrate
,20818965,C(max),"The results suggested that both the area under the plasma concentration-time curve (AUC((0-t)) = 46.83 +/- 11.09 microg/mL h) and the mean peak concentration of the test (C(max) = 4.63 +/- 1.71 microg/mL) were higher than the reference (AUC((0-t)) = 35.12 +/- 10.97 microg/mL h, C(max) = 2.11 +/- 0.08 microg/mL).",Preparation of fenofibrate immediate-release tablets involving wet grinding for improved bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20818965/),[μg] / [ml],2.11,234440,DB01039,Fenofibrate
,20818965,T(max),"Furthermore, the apparent rate of absorption of fenofibrate from the wet-milled tablet (T(max) = 2.63 hours) was faster than that from Lipanthyl (T(max) = 3.75 hours).",Preparation of fenofibrate immediate-release tablets involving wet grinding for improved bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20818965/),h,2.63,234441,DB01039,Fenofibrate
,20818965,T(max),"Furthermore, the apparent rate of absorption of fenofibrate from the wet-milled tablet (T(max) = 2.63 hours) was faster than that from Lipanthyl (T(max) = 3.75 hours).",Preparation of fenofibrate immediate-release tablets involving wet grinding for improved bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20818965/),h,3.75,234442,DB01039,Fenofibrate
,21882209,recovery,"The recovery was 90.3-94.7% and 83.3% for fenofibric acid and IS, respectively.",Development of a sensitive liquid chromatography/tandem mass spectrometry method for the determination of fenofibric acid in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21882209/),%,90.3-94.7,236086,DB01039,Fenofibrate
,21882209,recovery,"The recovery was 90.3-94.7% and 83.3% for fenofibric acid and IS, respectively.",Development of a sensitive liquid chromatography/tandem mass spectrometry method for the determination of fenofibric acid in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21882209/),%,83.3,236087,DB01039,Fenofibrate
,21882209,Total run time,Total run time for each sample analysis was 2.5 min.,Development of a sensitive liquid chromatography/tandem mass spectrometry method for the determination of fenofibric acid in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21882209/),min,2.5,236088,DB01039,Fenofibrate
,25588186,particle size,The mean particle size of SMEDDS formulation after dispersion was about 33.7nm,The In vitro and In vivo Evaluation of Fenofibrate with a Self-microemulsifying Formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25588186/),n,33.7,238284,DB01039,Fenofibrate
,25588186,maximum absorption,"Also, the maximum absorption was advanced (2h to 1.25h) with SMEDDS formulation.",The In vitro and In vivo Evaluation of Fenofibrate with a Self-microemulsifying Formulation. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25588186/),h,2,238285,DB01039,Fenofibrate
,25588186,maximum absorption,"Also, the maximum absorption was advanced (2h to 1.25h) with SMEDDS formulation.",The In vitro and In vivo Evaluation of Fenofibrate with a Self-microemulsifying Formulation. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25588186/),h,1.25,238286,DB01039,Fenofibrate
,25248304,bioavailability,"However, NLCs and SMEDDS increased the bioavailability of FNB to 705.11% and 809.10%, respectively, in comparison with Lipanthyl® capsules, although the relative bioavailability of FNB was only 366.05% after administration of SDPs.","The role of lipid-based nano delivery systems on oral bioavailability enhancement of fenofibrate, a BCS II drug: comparison with fast-release formulations. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25248304/),%,705.11,249116,DB01039,Fenofibrate
,25248304,bioavailability,"However, NLCs and SMEDDS increased the bioavailability of FNB to 705.11% and 809.10%, respectively, in comparison with Lipanthyl® capsules, although the relative bioavailability of FNB was only 366.05% after administration of SDPs.","The role of lipid-based nano delivery systems on oral bioavailability enhancement of fenofibrate, a BCS II drug: comparison with fast-release formulations. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25248304/),%,809.10,249117,DB01039,Fenofibrate
,25248304,relative bioavailability,"However, NLCs and SMEDDS increased the bioavailability of FNB to 705.11% and 809.10%, respectively, in comparison with Lipanthyl® capsules, although the relative bioavailability of FNB was only 366.05% after administration of SDPs.","The role of lipid-based nano delivery systems on oral bioavailability enhancement of fenofibrate, a BCS II drug: comparison with fast-release formulations. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25248304/),%,366.05,249118,DB01039,Fenofibrate
,25035071,drug,The drug entrapment efficiency was 99% with a loading capacity of 9.93 ± 0.01% (w/w).,Preparation and characterization of fenofibrate-loaded nanostructured lipid carriers for oral bioavailability enhancement. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25035071/),%,99,253902,DB01039,Fenofibrate
,25035071,entrapment efficiency,The drug entrapment efficiency was 99% with a loading capacity of 9.93 ± 0.01% (w/w).,Preparation and characterization of fenofibrate-loaded nanostructured lipid carriers for oral bioavailability enhancement. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25035071/),%,99,253903,DB01039,Fenofibrate
,25035071,loading capacity,The drug entrapment efficiency was 99% with a loading capacity of 9.93 ± 0.01% (w/w).,Preparation and characterization of fenofibrate-loaded nanostructured lipid carriers for oral bioavailability enhancement. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25035071/),%,9.93,253904,DB01039,Fenofibrate
,22283480,dissolution rate,"The dissolution rate of F1-F2 and Antara® capsules was 55.47 %, 61.27 % and 58.43 %, respectively, in 0.01 mol/L SDS solution over 60 min.",Improved dissolution rate and bioavailability of fenofibrate pellets prepared by wet-milled-drug layering. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22283480/),%,55.47,266838,DB01039,Fenofibrate
,22283480,dissolution rate,"The dissolution rate of F1-F2 and Antara® capsules was 55.47 %, 61.27 % and 58.43 %, respectively, in 0.01 mol/L SDS solution over 60 min.",Improved dissolution rate and bioavailability of fenofibrate pellets prepared by wet-milled-drug layering. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22283480/),%,61.27,266839,DB01039,Fenofibrate
,22283480,dissolution rate,"The dissolution rate of F1-F2 and Antara® capsules was 55.47 %, 61.27 % and 58.43 %, respectively, in 0.01 mol/L SDS solution over 60 min.",Improved dissolution rate and bioavailability of fenofibrate pellets prepared by wet-milled-drug layering. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22283480/),%,58.43,266840,DB01039,Fenofibrate
,22283480,C(max),"The C(max) of F1, F2 (8.21 ± 2.55 and 9.33 ± 2.37 μg/mL)and the AUC((0-t)) of F1, F2 (152.46 ± 78.89 and 172.17 ± 67.58 μg/mL·h)were higher than those of Antara® (6.02 ± 3.34 μg/mL and 89.82 ± 46.46 μg/mL·h) and, F1, F2 reached their C(max) earlier than Antara® (F1: 2.0 ± 1.1 h; F2: 1.8 ± 1.2 h; Antara®: 6.0 ± 8.9 h).",Improved dissolution rate and bioavailability of fenofibrate pellets prepared by wet-milled-drug layering. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22283480/),[μg] / [ml],8.21,266841,DB01039,Fenofibrate
,22283480,C(max),"The C(max) of F1, F2 (8.21 ± 2.55 and 9.33 ± 2.37 μg/mL)and the AUC((0-t)) of F1, F2 (152.46 ± 78.89 and 172.17 ± 67.58 μg/mL·h)were higher than those of Antara® (6.02 ± 3.34 μg/mL and 89.82 ± 46.46 μg/mL·h) and, F1, F2 reached their C(max) earlier than Antara® (F1: 2.0 ± 1.1 h; F2: 1.8 ± 1.2 h; Antara®: 6.0 ± 8.9 h).",Improved dissolution rate and bioavailability of fenofibrate pellets prepared by wet-milled-drug layering. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22283480/),[μg] / [ml],9.33,266842,DB01039,Fenofibrate
,22283480,AUC((0-t)),"The C(max) of F1, F2 (8.21 ± 2.55 and 9.33 ± 2.37 μg/mL)and the AUC((0-t)) of F1, F2 (152.46 ± 78.89 and 172.17 ± 67.58 μg/mL·h)were higher than those of Antara® (6.02 ± 3.34 μg/mL and 89.82 ± 46.46 μg/mL·h) and, F1, F2 reached their C(max) earlier than Antara® (F1: 2.0 ± 1.1 h; F2: 1.8 ± 1.2 h; Antara®: 6.0 ± 8.9 h).",Improved dissolution rate and bioavailability of fenofibrate pellets prepared by wet-milled-drug layering. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22283480/),[μg] / [h·ml],152.46,266843,DB01039,Fenofibrate
,22283480,AUC((0-t)),"The C(max) of F1, F2 (8.21 ± 2.55 and 9.33 ± 2.37 μg/mL)and the AUC((0-t)) of F1, F2 (152.46 ± 78.89 and 172.17 ± 67.58 μg/mL·h)were higher than those of Antara® (6.02 ± 3.34 μg/mL and 89.82 ± 46.46 μg/mL·h) and, F1, F2 reached their C(max) earlier than Antara® (F1: 2.0 ± 1.1 h; F2: 1.8 ± 1.2 h; Antara®: 6.0 ± 8.9 h).",Improved dissolution rate and bioavailability of fenofibrate pellets prepared by wet-milled-drug layering. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22283480/),[μg] / [h·ml],172.17,266844,DB01039,Fenofibrate
,22283480,AUC((0-t)),"The C(max) of F1, F2 (8.21 ± 2.55 and 9.33 ± 2.37 μg/mL)and the AUC((0-t)) of F1, F2 (152.46 ± 78.89 and 172.17 ± 67.58 μg/mL·h)were higher than those of Antara® (6.02 ± 3.34 μg/mL and 89.82 ± 46.46 μg/mL·h) and, F1, F2 reached their C(max) earlier than Antara® (F1: 2.0 ± 1.1 h; F2: 1.8 ± 1.2 h; Antara®: 6.0 ± 8.9 h).",Improved dissolution rate and bioavailability of fenofibrate pellets prepared by wet-milled-drug layering. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22283480/),[μg] / [ml],6.02,266845,DB01039,Fenofibrate
,22283480,AUC((0-t)),"The C(max) of F1, F2 (8.21 ± 2.55 and 9.33 ± 2.37 μg/mL)and the AUC((0-t)) of F1, F2 (152.46 ± 78.89 and 172.17 ± 67.58 μg/mL·h)were higher than those of Antara® (6.02 ± 3.34 μg/mL and 89.82 ± 46.46 μg/mL·h) and, F1, F2 reached their C(max) earlier than Antara® (F1: 2.0 ± 1.1 h; F2: 1.8 ± 1.2 h; Antara®: 6.0 ± 8.9 h).",Improved dissolution rate and bioavailability of fenofibrate pellets prepared by wet-milled-drug layering. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22283480/),[μg] / [h·ml],89.82,266846,DB01039,Fenofibrate
,22283480,AUC((0-t)),"The C(max) of F1, F2 (8.21 ± 2.55 and 9.33 ± 2.37 μg/mL)and the AUC((0-t)) of F1, F2 (152.46 ± 78.89 and 172.17 ± 67.58 μg/mL·h)were higher than those of Antara® (6.02 ± 3.34 μg/mL and 89.82 ± 46.46 μg/mL·h) and, F1, F2 reached their C(max) earlier than Antara® (F1: 2.0 ± 1.1 h; F2: 1.8 ± 1.2 h; Antara®: 6.0 ± 8.9 h).",Improved dissolution rate and bioavailability of fenofibrate pellets prepared by wet-milled-drug layering. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22283480/),h,2.0,266847,DB01039,Fenofibrate
,22283480,AUC((0-t)),"The C(max) of F1, F2 (8.21 ± 2.55 and 9.33 ± 2.37 μg/mL)and the AUC((0-t)) of F1, F2 (152.46 ± 78.89 and 172.17 ± 67.58 μg/mL·h)were higher than those of Antara® (6.02 ± 3.34 μg/mL and 89.82 ± 46.46 μg/mL·h) and, F1, F2 reached their C(max) earlier than Antara® (F1: 2.0 ± 1.1 h; F2: 1.8 ± 1.2 h; Antara®: 6.0 ± 8.9 h).",Improved dissolution rate and bioavailability of fenofibrate pellets prepared by wet-milled-drug layering. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22283480/),h,1.8,266848,DB01039,Fenofibrate
,22283480,AUC((0-t)),"The C(max) of F1, F2 (8.21 ± 2.55 and 9.33 ± 2.37 μg/mL)and the AUC((0-t)) of F1, F2 (152.46 ± 78.89 and 172.17 ± 67.58 μg/mL·h)were higher than those of Antara® (6.02 ± 3.34 μg/mL and 89.82 ± 46.46 μg/mL·h) and, F1, F2 reached their C(max) earlier than Antara® (F1: 2.0 ± 1.1 h; F2: 1.8 ± 1.2 h; Antara®: 6.0 ± 8.9 h).",Improved dissolution rate and bioavailability of fenofibrate pellets prepared by wet-milled-drug layering. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22283480/),h,6.0,266849,DB01039,Fenofibrate
,25877442,Tmax,"The median (range) Tmax- values of fenofibric acid were 4.5 h (3.0 - 8.0 h) and 3.25 h (1.0 - 6.5 h) after administration of the Lidose hard capsule and the nanoparticle tablet, respectively.",The Lidose hard capsule formulation of fenofibrate is suprabioavailable compared to the nanoparticle tablet formulation under high-fat fed conditions. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25877442/),h,4.5,269280,DB01039,Fenofibrate
,25877442,Tmax,"The median (range) Tmax- values of fenofibric acid were 4.5 h (3.0 - 8.0 h) and 3.25 h (1.0 - 6.5 h) after administration of the Lidose hard capsule and the nanoparticle tablet, respectively.",The Lidose hard capsule formulation of fenofibrate is suprabioavailable compared to the nanoparticle tablet formulation under high-fat fed conditions. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25877442/),h,3.25,269281,DB01039,Fenofibrate
